Overall Outcome: Stage I, Inter-Stage, and Stage II
The overall mortality rate, including Stage I (0%), inter-stage
interval (5 (8.3%)), and Stage II (6 (10.3%) was 18.6%. Figure 6
shows the Kaplan-Meier survival curves for the entire cohort, and for
patients who underwent either Stage I only, and both stages.
When analyzing the adverse events, we chose a composite of 30-day
mortality, stroke, paraplegia, myocardial infarction, and occurrence of
RRT. Univariate analysis after stage I showed a trend towards increasing
events in patients with history of smoking (53% vs. 43%) coronary
artery disease (26% vs 15%) or baseline neurologic abnormalities (40%
vs. 13%), as well as with prolonged intraoperative cardiopulmonary
bypass or DHCA time (Table 4).